| Genome-wide CRISPR screens reveal host factors critical for SARS-CoV-2 infection J Wei, MM Alfajaro, PC DeWeirdt, RE Hanna, WJ Lu-Culligan, WL Cai, ... Cell 184 (1), 76-91. e13, 2021 | 501 | 2021 |
| Identification of alternative splicing events regulated by the oncogenic factor SRSF1 in lung cancer FJ de Miguel, RD Sharma, MJ Pajares, LM Montuenga, A Rubio, R Pio Cancer research 74 (4), 1105-1115, 2014 | 106 | 2014 |
| Blockade of the complement C5a/C5aR1 axis impairs lung cancer bone metastasis by CXCL16-mediated effects D Ajona, C Zandueta, L Corrales, H Moreno, MJ Pajares, ... American journal of respiratory and critical care medicine 197 (9), 1164-1176, 2018 | 78 | 2018 |
| A large-scale analysis of alternative splicing reveals a key role of QKI in lung cancer FJ de Miguel, MJ Pajares, E Martínez-Terroba, D Ajona, X Morales, ... Molecular oncology 10 (9), 1437-1449, 2016 | 77 | 2016 |
| Genome-wide CRISPR screen reveals host genes that regulate SARS-CoV-2 infection J Wei, MM Alfajaro, RE Hanna, PC DeWeirdt, MS Strine, WJ Lu-Culligan, ... Biorxiv, 2020 | 66 | 2020 |
| Mammalian SWI/SNF chromatin remodeling complexes promote tyrosine kinase inhibitor resistance in EGFR-mutant lung cancer FJ de Miguel, C Gentile, WW Feng, SJ Silva, A Sankar, F Exposito, ... Cancer Cell 41 (8), 1516-1534. e9, 2023 | 45 | 2023 |
| EventPointer: an effective identification of alternative splicing events using junction arrays JP Romero, A Muniategui, FJ De Miguel, A Aramburu, L Montuenga, ... BMC genomics 17, 1-18, 2016 | 43 | 2016 |
| Tumor regression mediated by oncogene withdrawal or erlotinib stimulates infiltration of inflammatory immune cells in EGFR mutant lung tumors D Ayeni, B Miller, A Kuhlmann, PC Ho, C Robles-Oteiza, M Gaefele, ... Journal for immunotherapy of cancer 7, 1-15, 2019 | 35 | 2019 |
| A novel protein‐based prognostic signature improves risk stratification to guide clinical management in early‐stage lung adenocarcinoma patients E Martínez‐Terroba, C Behrens, FJ de Miguel, J Agorreta, E Monsó, ... The Journal of pathology 245 (4), 421-432, 2018 | 35 | 2018 |
| Comparison of RNA-seq and microarray platforms for splice event detection using a cross-platform algorithm JP Romero, M Ortiz-Estévez, A Muniategui, S Carrancio, FJ de Miguel, ... BMC genomics 19, 1-14, 2018 | 32 | 2018 |
| Inhibition of cytoplasmic EZH2 induces antitumor activity through stabilization of the DLC1 tumor suppressor protein BK Tripathi, MF Anderman, D Bhargava, L Boccuzzi, X Qian, D Wang, ... Nature communications 12 (1), 6941, 2021 | 14 | 2021 |
| ASCL1 Drives Tolerance to Osimertinib in EGFR Mutant Lung Cancer in Permissive Cellular Contexts B Hu, M Wiesehöfer, FJ de Miguel, Z Liu, LH Chan, J Choi, MA Melnick, ... Cancer research 84 (8), 1303-1319, 2024 | 8 | 2024 |
| Antiangiogenic vascular endothelial growth factor-blocking peptides displayed on the capsid of an infectious oncolytic parvovirus: assembly and immune interactions E Grueso, C Sánchez-Martínez, T Calvo-López, FJ de Miguel, ... Journal of Virology 93 (19), 10.1128/jvi. 00798-19, 2019 | 7 | 2019 |
| Overexpression of Malat1 drives metastasis through inflammatory reprogramming of the tumor microenvironment E Martinez-Terroba, LM Plasek-Hegde, I Chiotakakos, V Li, FJ de Miguel, ... Science Immunology 9 (96), eadh5462, 2024 | 5 | 2024 |
| Overexpressed Malat1 Drives Metastasis through Inflammatory Reprogramming of Lung Adenocarcinoma Microenvironment E Martínez-Terroba, FJ de Miguel, V Li, C Robles-Oteiza, K Politi, ... bioRxiv, 2023.03. 20.533534, 2023 | 2 | 2023 |
| B30 The Role of SMARCA4 as an EGFR-Independent Mechanism of Resistance to Osimertinib FJ De Miguel, B Hu, WL Cai, N Sun, MC Melnick, DX Nguyen, AZ Xiao, ... Journal of Thoracic Oncology 15 (2), S35-S36, 2020 | 1 | 2020 |
| P3. 07-007 Blockade of the Complement C5a/C5aR1 Axis Impairs Lung Cancer Bone Metastasis D Ajona, C Zandueta, L Corrales, H Moreno, M Pajares, S Ortiz-Espinosa, ... Journal of Thoracic Oncology 12 (11), S2300, 2017 | 1 | 2017 |
| Hypoxia is linked to acquired resistance to immune checkpoint inhibitors in lung cancer C Robles-Oteíza, K Hastings, J Choi, I Sirois, A Ravi, F Expósito, ... Journal of Experimental Medicine 222 (1), 2025 | | 2025 |
| Extreme selection constrains ability of EGFR-driven lung adenocarcinoma to diversify in response to erlotinib therapy JN Fisk, S Gaffney, K Politi, S Gettinger, F de Miguel, J Townsend Cancer Research 83 (7_Supplement), 126-126, 2023 | | 2023 |
| Overexpressed Malat1 Drives Metastasis through Inflammatory Reprogramming of Lung Adenocarcinoma Microenvironment EM Nez-Terroba, FJ de Miguel, V Li, C Robles-Oteiza, K Politi, ... bioRxiv: the preprint server for biology, 2023 | | 2023 |
